{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06145854",
            "orgStudyIdInfo": {
                "id": "2022-01"
            },
            "organization": {
                "fullName": "Midway Specialty Care Center",
                "class": "OTHER"
            },
            "briefTitle": "Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP",
            "officialTitle": "Real World Clinical Outcomes in Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP: An Observational, Multisite Prospective 2 Year Study in the Southern U.S.",
            "therapeuticArea": [
                "Infectious Diseases"
            ],
            "study": "cisgender-female-patients-who-start-on-long-acting-cabotegravir-for-prep"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-01-02",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-10-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-03-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-11-17",
            "studyFirstSubmitQcDate": "2023-11-17",
            "studyFirstPostDateStruct": {
                "date": "2023-11-24",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-26",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-30",
                "type": "ESTIMATED"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Emmanuelle Allseits",
                "investigatorTitle": "Physician",
                "investigatorAffiliation": "Midway Specialty Care Center"
            },
            "leadSponsor": {
                "name": "Midway Specialty Care Center",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "Oral PrEP regimens (FTC/TDF have been the mainstay of HIV prevention however patients now have more options for HIV prevention. In addition to oral PrEP regimens, the FDA approved the use of long acting Cabotegravir (CAB-LA) as the first long-acting medication for HIV prevention. This study will evaluate real world clinical outcomes of cisgender female patients who start CAB-LA for PrEP."
        },
        "conditionsModule": {
            "conditions": [
                "Hiv"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 100,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cisgender Females",
                    "interventionNames": [
                        "Drug: Cabotegravir Injection [Apretude]"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Cabotegravir Injection [Apretude]",
                    "description": "Apretude for PrEP",
                    "armGroupLabels": [
                        "Cisgender Females"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Describe the percent of cisgender females persistent on CAB-LA over 44 weeks.",
                    "timeFrame": "44 Weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Describe incidence of bacterial STIs through weeks 20, 44 and 92",
                    "timeFrame": "Weeks 20, 44 and 92"
                },
                {
                    "measure": "Describe satisfaction of cisgender female patients while being on CAB-LA through weeks 20, 44 and 92 with the use of satisfaction surveys",
                    "timeFrame": "Weeks 20, 44 and 92"
                },
                {
                    "measure": "Describe percentage adherence to CAB-LA injection schedule at weeks 20, 44 and 92 for cisgender females",
                    "timeFrame": "Weeks 20, 44 and 92"
                },
                {
                    "measure": "Describe percentage adherence to CAB-LA injection schedule at weeks 20, 44 and 92 for cisgender females with substance use and/or unstable housing.",
                    "timeFrame": "Weeks 20, 44 and 92"
                },
                {
                    "measure": "Describe percentage of cisgender female patients with HIV prevention failure while on CAB-LA, with detection of HIV, at weeks 20, 44 and 92.",
                    "timeFrame": "Weeks 20, 44 and 92"
                },
                {
                    "measure": "Describe percentage of cisgender female patients with weight gain > 10% from baseline on CAB-LA at weeks 20, 44 and 92",
                    "timeFrame": "Weeks 20, 44 and 92"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Cisgender females, ages 18 years and older\n2. Negative HIV test at baseline\n3. Negative Pregnancy test at baseline\n4. Weigh at least 35 kilograms\n5. Already Prescribed CAB-LA (Apretude)\n\nExclusion Criteria:\n\n1. Transgender females or males\n2. Cisgender males\n3. Cisgender female who is actively breastfeeding\n4. Severe hepatotoxicity\n5. Evidence of Hepatitis B Infection\n6. History or presence of allergies to cabotegravir or its components",
            "sex": "FEMALE",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "100 cisgender females (including 15 cisgender females with history of substance use and 15 cisgender females with unstable housing)",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "locations": [
                {
                    "facility": "Midway Specialty Care Center",
                    "status": "RECRUITING",
                    "city": "Orlando",
                    "state": "Florida",
                    "zip": "32819",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jennifer Kuretski",
                            "role": "CONTACT",
                            "phone": "407-745-1171",
                            "email": "jkuretski@midwaycare.org"
                        },
                        {
                            "name": "Emmanuelle Allseits, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.53834,
                        "lon": -81.37924
                    }
                },
                {
                    "facility": "Midway Specialty Care Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Temple Terrace",
                    "state": "Florida",
                    "zip": "33617",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jennifer Kuretski",
                            "role": "CONTACT",
                            "email": "jkuretski@midwaycare.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.0353,
                        "lon": -82.38926
                    }
                },
                {
                    "facility": "Midway Specialty Care Center",
                    "status": "RECRUITING",
                    "city": "West Palm Beach",
                    "state": "Florida",
                    "zip": "33401",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jennifer Kuretski",
                            "role": "CONTACT",
                            "phone": "561-249-2279",
                            "email": "jkuretski@midwaycare.org"
                        },
                        {
                            "name": "Jennifer Kuretski, DNP",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 26.71534,
                        "lon": -80.05337
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M3522",
                    "name": "Acquired Immunodeficiency Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M18250",
                    "name": "HIV Infections",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000584914",
                    "term": "Cabotegravir"
                }
            ],
            "ancestors": [
                {
                    "id": "D000019428",
                    "term": "HIV Integrase Inhibitors"
                },
                {
                    "id": "D000019429",
                    "term": "Integrase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000019380",
                    "term": "Anti-HIV Agents"
                },
                {
                    "id": "D000044966",
                    "term": "Anti-Retroviral Agents"
                },
                {
                    "id": "D000000998",
                    "term": "Antiviral Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M254021",
                    "name": "Cabotegravir",
                    "asFound": "Cleft",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21386",
                    "name": "Integrase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M21385",
                    "name": "HIV Integrase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M21350",
                    "name": "Anti-HIV Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M25428",
                    "name": "Anti-Retroviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4314",
                    "name": "Antiviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}